InspireMD, Inc. announced that it will host a conference call and webcast on Tuesday, November 12, 2019, to discuss financial results for the third quarter and nine months ended September 30, 2019, and provide a corporate update.
TEL AVIV, Israel, Nov. 05, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, November 12, 2019, to discuss financial results for the third quarter and nine months ended September 30, 2019, and provide a corporate update.
Conference Call & Webcast:
Tuesday, November 12th @ 8:30am Eastern Time
Within the US: | 877-451-6152 |
Outside the US: | 201-389-0879 |
Conference ID: | 13695583 |
Webcast: | http://public.viavid.com/index.php?id=136553 |
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com